Literature DB >> 3117593

Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins.

S G Awadalla1, C I Friedman, N W Chin, W Dodds, J M Park, M H Kim.   

Abstract

Multiple follicular stimulation is a prerequisite to the efficient use of in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT). For some individuals, however, this stimulation may be difficult using standard superovulation protocols because of dominant follicle formation, suboptimal estradiol response, or premature luteinizing hormone surge. A group of such individuals with several previous failed attempts at superovulation were studied. Follicular stimulation was accomplished using a long-acting agonist of gonadotropin-releasing hormone (GnRH) for pituitary suppression followed by human menopausal gonadotropin (hMG) for follicular stimulation. Fourteen cycles (12 IVF, 2 GIFT) were completed in 12 individuals. There were no cycle cancellations. Mean number of prior cycle cancellations per patient was 3.1 +/- 0.4. Mean number of mature oocytes recovered was 3.9 +/- 0.5. Two pregnancies resulted. Pituitary suppression with a long-acting agonist of GnRH followed by hMG appears to be an effective adjunct to current superovulation regimens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117593     DOI: 10.1016/s0015-0282(16)59536-3

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

1.  Isolation, in vitro maturation, and fertilization of germinal vesicle oocytes obtained from the intact murine ovary.

Authors:  G W Randall; S G Awadalla; C A Shivers
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-12

2.  Efficiency and cost effectiveness of three protocols for gamete transfer.

Authors:  S G Awadalla; G W Randall
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12

3.  Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.

Authors:  M C Edelstein; R G Brzyski; G S Jones; S Oehninger; S M Sieg; S J Muasher
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-06

4.  The use of gonadotropin releasing hormone agonist (GnRHa) in good responders undergoing repeat in vitro fertilization/embryo transfer (IVF/ET).

Authors:  J H Segars; G A Hill; S H Bryan; C M Herbert; K G Osteen; B J Rogers; A C Wentz
Journal:  J In Vitro Fert Embryo Transf       Date:  1990-12

5.  Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response.

Authors:  Selmo Geber; Liana Sales; Marcos A C Sampaio
Journal:  J Assist Reprod Genet       Date:  2002-07       Impact factor: 3.412

6.  High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.

Authors:  G E Hofmann; J P Toner; S J Muasher; G S Jones
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

7.  Elevated serum progesterone values at the time of ovulation induction in luteal leuprolide acetate-down-regulated GIFT cycles are associated with decreased clinical pregnancy rates.

Authors:  G W Randall; P A Gantt; D Gantt; M J Kirk; N Romines
Journal:  J Assist Reprod Genet       Date:  1996-07       Impact factor: 3.412

8.  The effect of leuprolide acetate on steroidogenesis by granulosa and theca cells in vitro.

Authors:  J L Frederick; M J Hickey; M M Francis; M V Sauer; R J Paulson
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-08

9.  A randomized prospective study on the effect of short and long buserelin treatment in women with repeated unsuccessful in vitro fertilization (IVF) cycles due to inadequate ovarian response.

Authors:  M Dirnfeld; Y Gonen; A Lissak; S Goldman; M Koifman; Y Sorokin; H Abramovici
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12

Review 10.  Clinical uses of gonadotropin-releasing hormone analogues.

Authors:  R F Casper
Journal:  CMAJ       Date:  1991-01-15       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.